Cancer survival rates higher than previously assumed

October 10, 2002

Conventional estimates for life expectancy after cancer diagnosis have been too pessimistic, suggests a study in this week's issue of THE LANCET.

There are two main ways of quantifying survival estimates after cancer diagnosis. The conventional method, known as the cohort method, is based on the survival experience of cancer patients whose diagnosis occurred many years ago. This method therefore fails to disclose recent improvements in cancer detection and treatment. A recently developed alternative survival assessment-called period analysis-provides more up-to-date estimates of cancer survival, as it exclusively uses survival data from a specific time period, such as a particular year.

Hermann Brenner from the German Centre for Research on Ageing, Heidelberg, Germany, compared survival estimates obtained with period analysis (for the year 1998) and cohort analysis (for patients diagnosed between 1978 and 1993) using data from the US population based cancer registries.

Estimates of 5-year, 10-year, 15-year, and 20-year relative survival rates for all types of cancer were 63%, 57%, 53%, and 51%, respectively, by period analysis. These estimates were 1%, 7%, 11%, and 11% higher, respectively, than corresponding estimates by cohort-based survival analysis. By period analysis, 20-year relative survival rates were close to 90% for thyroid and testicular cancer, exceeded 80% for melanomas and prostate cancer, were about 80% for endometrial cancer, and almost 70% for bladder cancer and Hodgkin's disease. A 20-year relative survival rate of 65% was estimated for breast cancer, of 60% for cervical cancer, and of about 50% for colorectal, ovarian, and kidney cancer.

Hermann Brenner comments: "The provision of up-to-date long-term survival rates is not merely an academic exercise-it could help to prevent clinicians and their patients from undue discouragement or depression by outdated and often overly pessimistic survival expectations. Timely detection of improvements in long-term survival rates also adds to the value of cancer surveillance as a basis for appropriate public-health decisions."
-end-
Contact: Professor Hermann Brenner, Department of Epidemiology,Deutsches Zentrum fur Alternsforschung (DZFA),Bergheimer Strasse 20,D-69115 Heidelberg,Germany;T) +49 6221 54 8140;F)+49 6221 54 8142;E) brenner@dzfa.uni-heidelberg.de

Lancet

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.